Two Years of Remission and a Question of How Long Is Long Enough
A single patient in sustained histologic remission, asking to stop the twice-daily regimen that got her there. The disagreement isn't whether she's earned a conversation about stopping — it's whether stopping and stepping down are the same offer, or two different bets with two different odds.
Danielle K., now 16, has spent two years timing her school day around a steroid inhaler she swallows instead of breathes in — twice daily, no food or drink for thirty minutes after, a routine she's kept up quietly enough that most of her friends don't know she has a chronic esophageal disease at all. It worked: eighteen months of biopsies have held at 3 eosinophils per high-power field, comfortably under the 15/hpf remission threshold, after two years of intermittent food-sticking that led to her diagnosis at 14. What's changed isn't her disease — it's her calendar. She leaves for college in ten months, and she's asked, directly and more than once, whether she actually has to keep doing this once she's on her own.
The honest complication is that "stopping" and "cutting back" aren't the same request, even though Danielle has been treating them as interchangeable. EoE's relapse behavior after therapy is withdrawn is well described in the literature Straumann's group and others built defining the disease's chronic, relapsing course, and a full stop after complete remission carries a materially different recurrence risk than a dose reduction that keeps some ongoing suppression in place. There's also a detail specific to the newer, FDA-approved formulation in this space worth naming precisely: its own label restricts use to twelve weeks, with no data behind it past that point — a real asymmetry, since Danielle's actual two years of experience is with the older swallowed fluticasone, not that product, but it's a useful marker of just how little maintenance-phase data exists industry-wide for any topical option in EoE.
Her own history adds one more concrete data point worth weighing directly rather than treating as background: eight months ago she developed a mild episode of oral thrush, caught early and treated without incident, a known and generally minor risk of prolonged local corticosteroid exposure rather than anything more serious. It hasn't recurred since, and her growth and bone development have otherwise tracked normally for her age — but a second thrush episode during whatever regimen she ends up on would be a real, tangible cost of staying the current course, not just a hypothetical one, and it's the kind of thing a lower dose would be expected to reduce even if it doesn't eliminate it outright.
Two years in, planning for a routine she won't be able to keep
I'd rather run a controlled discontinuation trial now, with a scope at three months, than let her attempt an uncontrolled one on her own timeline once she's away. Eighteen months of remission is a genuinely long run, and if she's going to stop eventually, doing it while we can still see her easily is the safer version of the same decision.
The relapse pattern after full topical-steroid withdrawal in EoE tends to show up reasonably quickly once the drug is out of the picture — not a slow drift, a real return. I'd rather step her down to once-daily than stop outright, so she's not walking into her first semester managing a full relapse instead of a half-dose.
A scoped stop is safer than an unscoped one, I agree — but "safer than the worse version of stopping" isn’t the same argument as "safe enough to try." I’d rather not test how quickly she relapses when a smaller step gets most of the burden relief she’s actually asking for.
I want to name something underneath both of your positions: the actual long-term maintenance data for topical steroids in EoE is thinner than two years of Danielle's own good response makes it feel. Even the newer FDA-approved oral suspension is labeled for twelve weeks, with no trial evidence past that point — a different product than hers, but a real marker of how little anyone in this field actually knows about year-three, year-four dosing.
That argues for the step-down, not because it splits the difference, but because it's the option that commits us to the least based on data neither of you has as solidly as it might feel like you do — it buys real information about her own relapse risk without either fully testing it or fully avoiding the question.
Agreed: step down from twice-daily to once-daily fluticasone, with repeat endoscopy and biopsy at four months — before she leaves for school — to confirm remission is holding at the lower dose.
Not agreed, carried forward rather than resolved today:
The gastroenterologist would consider a full discontinuation trial before she leaves, arguing a successful step-down is itself evidence she can tolerate less drug.
The allergist would keep her on once-daily maintenance through at least her first semester, arguing that a stable four months on a reduced dose says less about a full stop than it looks like it does.
Danielle leaves the visit with a real answer for the next four months and an open question for the one after that — which her own biopsy result, not a preset plan, will settle.